fda compounding semaglutide warning letters october 2025 issued 25 to telehealth companies for false and misleading claims about compounded GLP-1 products. Unlike FDA-approved drugs, these products have not been proven to be safe, effective, or of fda glp-1 warning letters october

Typically, a patient starts at a low dose (0.25 mg) for four weeks to allow the body to adjust before moving to a higher dose

The Most Important Thing to Understand First IVY RX's program may provide access to a compounded injectable GLP-1 medication if a licensed clinician determines it is appropriate for you

Furthermore, most professional medical insurance providers in the UK wont cover practitioners using unlicensed products, leaving patients vulnerable if a complication occurs

For instance, in the SURPASS trials 1 , patients taking tirzepatide experienced up to 20.2% body weight reduction , compared to around 13.7% for semaglutide

wk: weeks